Department of Gastroenterology, The Third People's Hospital of Chengdu, Chengdu, Sichuan, PR China.
4 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Retrospective cohort study with clear outcome definition and statistically significant associations between weight gain and FIB-4 increase in a defined population, but limited by observational design and surrogate endpoint (FIB-4 rather than fibrosis progression or clinical liver outcomes).
This is a small pilot cross-sectional and longitudinal study with a single-arm design and no randomized control, identifying protein signatures and post-hoc mechanistic associations that require confirmatory evidence in an independent cohort.
Single case report of adebrelimab-induced liver injury with RUCAM causality assessment; demonstrates clinical utility of diagnostic tool but provides no comparative efficacy data or population estimates.
Mechanistic study in primary human B cells and mice identifying TLR4–spike interaction as a metabolic checkpoint, but lacks clinical efficacy data, controlled comparisons of effect sizes, or validation in vivo; findings are pathway-descriptive rather than practice-changing.